Ropes & Gray represented Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) in its $200 million secondary offering. The transaction closed on Nov. 18.
Zai Lab is a commercial-stage biopharmaceutical company based in China and the United States. The company is focused on discovering, developing, and commercializing innovative products in the areas of oncology, immunology, neuroscience and infectious diseases.
The deal team included capital markets partner Tom Danielski, M&A partner Arthur Mok, litigation & enforcement partner Geoff Atkins, IP transactions partner Melissa Rones, and life sciences partner Katherine Wang.
